Skip To Main Content
Debu Tripathy on Muck Rack

Debu Tripathy

Houston
As seen in: Nature, Taylor & Francis Online, JAMA Oncology, BioRxiv, MedPage Today, The Lancet, HemOnc Today, NewsBreak, CURE Magazine, ONCOLOGY journal and
Professor and Chair, Dept. of Breast Medical Oncology at @MDAndersonNews. Tweets are my own. #breastcancer #endcancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Debu

Contact Debu, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

AI-derived tumor-infiltrating lymphocytes enhance the prediction of pathologic complete response in early-stage triple-negative breast cancer

|
By Xiaoxi Pan, Caner Ercan, Zhongya Wang, Roland Bassett, Karina Gonzales, Gaiane M. Rauch, Beatriz E. Adrada, Rosalind Candelaria, Debu Tripathy, Jennifer K. Litton, Sharon H. Giordano, Vicente Valero, Banu Arun, Alyson R. Clayborn, Jason WHite, Jason White, Qingqing Ding, Aysegul Sahin, William Fraser Symmans, Clinton Yam, Lei Huo, Yinyin Yuan, Kiran Virani
| Nature Verified
Abstract Stromal tumor-infiltrating lymphocytes (sTILs) may hold clinical value for triple-negative breast cancer (TNBC) for outcome prediction. Manual scoring of sTILs suffers from inter-observer variability, limiting its clinical adoption.
Open in Who Shared Issue with article?

Serum S100A8/S100A9 is associated with increased risk of brain metastasis in patients with inflammatory breast cancer

|
By Emilly S. Villodre, Juhee Song, Xiaoding Hu, Kristen Gomez, Evan Cohen Verified, James M. Reuben, Azadeh Nasrazadani, Debu Tripathy, Wendy A. Woodward, Savitri Krishnamurthy, Bisrat G. Debeb
| Nature Verified
Abstract Inflammatory breast cancer (IBC) is a rare but highly aggressive breast cancer with a strong propensity to metastasize, including to the brain. Higher serum levels of S100A8/A9, especially S100A9, have been linked to poor outcomes and treatment resistance in aggressive breast cancers, but their role in IBC remains undefined. This study evaluated whether serum S100A8/A9 levels are associated with clinical outcomes in patients with IBC.
Open in Who Shared Issue with article?

Ecotypes of triple-negative breast cancer in response to chemotherapy

|
By Yun Yan, Yiyun Lin, Tapsi Kumar, Shanshan Bai, Aatish Thennavan, Jianzhuo Li, Emi Sei, TUẤN TRẦN, Tuan Tran, Min Hu, Mitchell Rao, Chenling Tang, Siyuan He, Anna K Casasent, Debu Tripathy, Alastair Thompson, Lei Huo, Stacy L. Moulder, Clinton Yam, Nicholas E Navin, Elizabeth Ravenberg, Gaiane Margishvili Rauch, Alyson R. Clayborn
| Nature Verified
Abstract Triple-negative breast cancer (TNBC) is an aggressive subtype that is frequently treated with chemotherapy, but only half of the patients respond well and have good clinical outcome1,2. Here we leveraged pretreatment tissue samples from treatment-naive patients with TNBC who received neoadjuvant chemotherapy and performed single-cell transcriptomic analysis of 427,857 cells from 101 patients and spatial transcriptomic analysis of 44 patients.
Open in Who Shared Issue with article?
See all 37 licensed articles (158 Total)